CPA
AUPH icon

Capital Performance Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Capital Performance Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,181
Closed -$8.66K – 393
2024
Q3 		$8.66K Buy
+1,181
New +$7.32K ﹤0.01% 892

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Performance Advisors's AUPH Position: Q4 2024 in Review

Capital Performance Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2024, closing a stake of 1,181 shares — an estimated $8.66K sold.

Capital Performance Advisors first reported a position in AUPH in Q3 2024 and held it in 1 quarter. The position peaked at $8.66K in Q3 2024. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

  • Capital Performance Advisors reported no remaining Aurinia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,181 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $8.66K.
  • Capital Performance Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Aurinia Pharmaceuticals position peaked at $8.66K in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.